Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes

NCT06916611 · tracked via the Priya Life Science China tracker

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Phase

Observational

Started

2023-05-01

Last updated

2025-04-08

Condition(s) studied

HFpEFHeart Failure With Preserved Ejection Fraction

Investigational drug(s) / intervention(s)

Cardiac Magnetic Resonance Imaging

Cardiac Magnetic Resonance Imaging: This study included patients who were diagnosed with HFpEF and had completed CMR.

Study summary

Using cardiac magnetic resonance imaging technology, the ejection fraction of heart failure (HFpEF) and different subtypes of cardiac magnetic resonance characteristics, and combined with the clinical characteristics and prognosis of the patient, explore the value of cardiac magnetic resonance in disease diagnosis, classification, treatment and prognosis, and provide new ideas for clinical practice.

Eligibility

Sex

ALL

Min age

50 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age is 50 years old. * Cardiac color ultrasound shows an ejection fraction (EF) of 50% or more. * Symptoms / signs of heart failure and increased natriuretic peptide levels during hospitalization / visit (BNP 100 pg/mL or NT-proBNP 400 pg / mL). Exclusion Criteria: * Severe liver and kidney insufficiency * Severe valvular heart disease (severe, severe severe) or known infiltrative or hypertrophic cardiomyopathy * Malignant tumors and severe hematological diseases * severe infection * Autoimmune system diseases

Primary outcome measure(s)

Rate of Cardiovascular death — follow - up every 6 months; up to 24 - months
Rate of readmission of heart failure — follow - up every 6 months; up to 24 - months

Trial sites (1)

Facility	City	Region	Status
the Affiliated Hospital of Xuzhou Medical University	Xuzhou	Jiangsu

More The Affiliated Hospital of Xuzhou Medical University trials in China

Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) Recruiting

Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma Starting soon

Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma Recruiting

Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL Recruiting

Surgical-imaging Research on Obesity (SIRO) Recruiting

Other trials for the same condition

A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction Recruiting

Study on Heart Failure with Preserved Ejection Fraction with Qishen Granules Recruiting

Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction Recruiting

Study of JK07 in Patients With Chronic Heart Failure Active, not recruiting

Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06916611 on ClinicalTrials.gov ↗ ← All trials in China